Sign Up to like & get
recommendations!
1
Published in 2022 at "Clinical and translational science"
DOI: 10.1111/cts.13280
Abstract: Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is a novel oral carbapenem prodrug of tebipenem (TBP), the active moiety, currently in development for treating serious bacterial infections. This study assessed the bioequivalence (BE) of the clinical trial and…
read more here.
Keywords:
tablet;
clinical trial;
tbp hbr;
pivoxil hydrobromide ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00590-22
Abstract: Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral carbapenem prodrug being developed for the treatment of serious bacterial infections. The active moiety, tebipenem, has broad-spectrum activity against common Enterobacterales pathogens, including extended-spectrum-β-lactamase (ESBL)-producing multidrug-resistant strains. ABSTRACT…
read more here.
Keywords:
tebipenem pivoxil;
tebipenem;
tbp hbr;
pivoxil hydrobromide ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01509-22
Abstract: Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral prodrug of pharmacologically active moiety tebipenem (TBP), which is a carbapenem with activity against multidrug-resistant Gram-negative pathogens. Conversion from the prodrug to the active moiety, namely, TBP, occurs…
read more here.
Keywords:
tbp;
tebipenem pivoxil;
tbp hbr;
pivoxil hydrobromide ... See more keywords